TY - JOUR T1 - Cardiac scintigraphy with 99mTc-diphosphonates in cardiac amyloidosis JO - Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) T2 - AU - de Haro-del Moral,F.J. AU - Pubul-Núñez,V. AU - Casáns-Tormo,I. AU - Jiménez-Heffernan,A. AU - Ruano-Pérez,R. SN - 22538089 M3 - 10.1016/j.remnie.2020.06.006 DO - 10.1016/j.remnie.2020.06.006 UR - https://www.elsevier.es/en-revista-revista-espanola-medicina-nuclear-e-425-articulo-cardiac-scintigraphy-with-99mtc-diphosphonates-in-S2253808920300677 AB - Transthyretin cardiac amyloidosis (ATTR) has traditionally been considered a rare, difficult-to-diagnose and untreatable disease. However, its prevalence is known to be greater than what was previously thought, non-invasive diagnostic methods are available, and that effective treatments are emerging. In this context, cardiac scintigraphy (CS) with 99mTc-labeled diphosphonates has aroused a noticeable surge in interest by demonstrating high sensitivity and specificity for the reliable, non-invasive diagnosis of ATTR. By way of a guide, this article aims to identify the critical components in the performance of CS that are useful in everyday clinical practice and, thus, help specialists use optimal radiopharmaceuticals, obtain the most appropriate images, interpret the results thereof, and acquaint themselves with those clinical scenarios in which it is convenient to perform CS. ER -